Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor

Patent metadata

Field	Value
Publication number	US-2016355583-A1
Application number	US-201615165150-A
Country	US
Kind code	A1
Filing date	May 26, 2016
Priority date	Jun 5, 2015
Publication date	Dec 8, 2016
Grant date	—

Abstract

The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.

First claim

What is claimed is:

1 . An isolated antibody or antigen-binding fragment thereof, which binds human BMP9 and comprises:
(a) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 61, 62 and 63, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 71, 72 and 73, respectively; (b) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 64, 65 and 66, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 74, 75 and 76, respectively; (c) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 1, 2 and 3, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 11, 12 and 13, respectively; (d) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 4, 5 and 6, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 14, 15 and 16, respectively; (e) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 21, 22 and 23, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 31, 32 and 33, respectively; (f) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 24, 25 and 26, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 34, 35 and 36, respectively; (g) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 41, 42 and 43, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 51, 52 and 53, respectively; (h) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 44, 45 and 46, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 54, 55 and 56, respectively; (i) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 81, 82 and 83, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 91, 92 and 93, respectively; (j) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 84, 85 and 86, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 94, 95 and 96, respectively; (k) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 101, 102 and 103, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 111, 112 and 113, respectively; (l) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 104, 105 and 106, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 114, 115 and 116, respectively; (m) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 121, 122 and 123, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 131, 132 and 133, respectively; (n) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 124, 125 and 126, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 134, 135 and 136, respectively; (o) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 141, 142 and 143, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 151, 152 and 153, respectively; (p) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 144, 145 and 146, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 154, 155 and 156, respectively; (q) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 161, 162 and 163, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 171, 172 and 173, respectively; or (r) the HCDR1, HCDR2, and HCDR3 sequences of SEQ ID NOs: 164, 165 and 166, respectively, and the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID NOs: 174, 175 and 176, respectively.

2 . The isolated antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) A VH sequence of SEQ ID NO: 67; (b) A VH sequence of SEQ ID NO: 7; (c) A VH sequence of SEQ ID NO: 27; (d) A VH sequence of SEQ ID NO: 47; (e) A VH sequence of SEQ ID NO: 87; (f) A VH sequence of SEQ ID NO: 107; (g) A VH sequence of SEQ ID NO: 127; (h) A VH sequence of SEQ ID NO: 147; or (i) A VH sequence of SEQ ID NO: 167.

3 . The isolated antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) A VL sequence of SEQ ID NO: 77; (b) A VL sequence of SEQ ID NO: 17; (c) A VL sequence of SEQ ID NO: 37; (d) A VL sequence of SEQ ID NO: 57; (e) A VL sequence of SEQ ID NO: 97; (f) A VL sequence of SEQ ID NO: 117; (g) A VL sequence of SEQ ID NO: 137; (h) A VL sequence of SEQ ID NO: 157; or (i) A VL sequence of SEQ ID NO: 177.

4 . The isolated antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) A VH sequence of SEQ ID NO: 67 and a VL sequence of SEQ ID NO: 77; (b) A VH sequence of SEQ ID NO: 7 and a VL sequence of SEQ ID NO: 17; (c) A VH sequence of SEQ ID NO: 27 and a VL sequence of SEQ ID NO: 37; (d) A VH sequence of SEQ ID NO: 47 and VL sequence of SEQ ID NO: 57; (e) A VH sequence of SEQ ID NO: 87 and a VL sequence of SEQ ID NO: 97; (f) A VH sequence of SEQ ID NO: 107 and a VL sequence of SEQ ID NO: 117; (g) A VH sequence of SEQ ID NO: 127 and a VL sequence of SEQ ID NO: 137; (h) A VH sequence of SEQ ID NO: 147 and VL sequence of SEQ ID NO: 157; or (i) A VH sequence of SEQ ID NO: 167 and a VL sequence of SEQ ID NO: 177.

5 . The isolated antibody or antigen-binding fragment thereof of claim 1 , comprising:
(d) A heavy chain sequence of SEQ ID NO: 69; (b) A heavy chain sequence of SEQ ID NO: 9; (a) A heavy chain sequence of SEQ ID NO: 29; (c) A heavy chain sequence of SEQ ID NO: 49; (e) A heavy chain sequence of SEQ ID NO: 89; (f) A heavy chain sequence of SEQ ID NO: 109; (g) A heavy chain sequence of SEQ ID NO: 129; (h) A heavy chain sequence of SEQ ID NO: 149; or (i) A heavy chain sequence of SEQ ID NO: 169.

6 . The isolated antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) A light chain sequence of SEQ ID NO: 79; (b) A light chain sequence of SEQ ID NO: 19; (c) A light chain sequence of SEQ ID NO: 39; (d) A light chain sequence of SEQ ID NO: 59; (e) A light chain sequence of SEQ ID NO: 99; (f) A light chain sequence of SEQ ID NO: 119; (g) A light chain sequence of SEQ ID NO: 139; (h) A light chain sequence of SEQ ID NO: 159; or (i) A light chain sequence of SEQ ID NO: 179.

7 . The isolated antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) A heavy chain sequence of SEQ ID NO: 69; and a light chain sequence of SEQ ID NO: 79; (b) A heavy chain sequence of SEQ ID NO: 9; and a light chain sequence of SEQ ID NO: 19; (c) A heavy chain sequence of SEQ ID NO: 29; and a light chain sequence of SEQ ID NO: 39; (d) A heavy chain sequence of SEQ ID NO: 49; and a light chain sequence of SEQ ID NO: 59; (e) A heavy chain sequence of SEQ ID NO: 89; and a light chain sequence of SEQ ID NO: 99; (f) A heavy chain sequence of SEQ ID NO: 109; and a light chain sequence of SEQ ID NO: 119; (g) A heavy chain sequence of SEQ ID NO: 129; and a light chain sequence of SEQ ID NO: 139; (h) A heavy chain sequence of SEQ ID NO: 149; and a light chain sequence of SEQ ID NO: 159; or (i) A heavy chain sequence of SEQ ID NO: 169; and a light chain sequence of SEQ ID NO: 179.

8 . The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the isolated antibody or antigen-binding fragment is an IgG, or is derived from an IgG.

9 . The isolated antibody or antigen-binding fragment thereof of claim 8 , wherein the IgG is selected from the group consisting of an IgG1, an IgG2, an IgG3 and an IgG4.

10 . The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the isolated antibody or antigen-binding fragment is selected from the group consisting of: a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab and a scFv.

11 . The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the isolated antibody or antigen-binding fragment thereof is a component of an immunoconjugate.

12 . The isolated antibody or antigen-binding fragment thereof o

Assignees

• Chen Zijun
• Deng Sujun
• He Yun
• Huang Dagang
• Kugler Markus
• Li Qian
• Lu Chris Xiangyang
• Luo Xiao
• Shan Yongqiang
• Tissot-Daguette Kathrin Ulrike
• Wu Jing
• Novartis Ag

Inventors

• Chen Zijun
• Deng Sujun
• He Yun
• Huang Dagang
• Kugler Markus
• Li Qian
• Lu Chris Xiangyang
• Luo Xiao
• Shan Yongqiang
• Tissot-Daguette Kathrin Ulrike
• Wu Jing

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K2039/505

  comprising antibodies · CPC title